It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
AZN (@Pharmaceuticals: Major) experienced а +1.12% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.02% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.17%. For the same industry, the average monthly price growth was +1.79%, and the average quarterly price growth was -8.34%.
AZN is expected to report earnings on Feb 08, 2024.
NVS is expected to report earnings on Jan 31, 2024.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
|AZN||NVS||AZN / NVS|
overvalued / fair valued / undervalued
PROFIT vs RISK RATING
PRICE GROWTH RATING
P/E GROWTH RATING
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (8) in the Pharmaceuticals Major industry is in the same range as AZN (17). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
NVS's Profit vs Risk Rating (10) in the Pharmaceuticals Major industry is in the same range as AZN (12). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
AZN's SMR Rating (55) in the Pharmaceuticals Major industry is in the same range as NVS (56). This means that AZN’s stock grew similarly to NVS’s over the last 12 months.
NVS's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as AZN (58). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.
NVS's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for AZN (94). This means that NVS’s stock grew significantly faster than AZN’s over the last 12 months.
6 days ago70%
1 day ago48%
1 day ago51%
1 day ago39%
1 day ago58%
1 day ago53%
1 day ago57%
1 day ago49%
1 day ago55%
1 day ago43%
1 day ago44%
1 day ago42%
2 days ago54%
2 days ago45%
8 days ago48%
8 days ago45%
1 day ago57%
1 day ago37%
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with MRK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then MRK could also see price increases.